Delving into the Latest Updates on Shanghai Juyuan Biotechnology Co., Ltd. with Synapse

Overview

[Translation] A multicenter, open-label, first-in-human Phase I clinical study evaluating the safety, pharmacokinetics, and preliminary antitumor activity of INV-6452 in adult patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced/metastatic breast cancer or locally advanced/metastatic solid tumors

确定推荐剂量范围和/或最大耐受剂量，并评估INV-6452口服给药在晚期/转移性HR+/HER2-乳腺癌或局部晚期/转移性实体瘤成年患者中的剂量限制性毒性；评估INV-6452在晚期/转移性HR+/HER2-乳腺癌或局部晚期/转移性实体瘤成年患者中的安全性、耐受性、PK/PD特征和初步抗肿瘤活性。

[Translation]

To determine the recommended dose range and/or maximum tolerated dose and evaluate the dose-limiting toxicities of oral INV-6452 in adult patients with advanced/metastatic HR+/HER2- breast cancer or locally advanced/metastatic solid tumors; to evaluate the safety, tolerability, PK/PD characteristics and preliminary antitumor activity of INV-6452 in adult patients with advanced/metastatic HR+/HER2- breast cancer or locally advanced/metastatic solid tumors.

Start Date-

Sponsor / Collaborator

Shanghai Juyuan Biotechnology Co., Ltd.

[+3]

100 Clinical Results associated with Shanghai Juyuan Biotechnology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shanghai Juyuan Biotechnology Co., Ltd.

Login to view more data

100 Deals associated with Shanghai Juyuan Biotechnology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shanghai Juyuan Biotechnology Co., Ltd.

Login to view more data